Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sovleplenib in adult immune thrombocytopenia
NCT03951623Phase 1Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Aug 2019
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of sovleplenib in immune thrombocytopenia (ITP) (4 arms), sponsored by Hutchison MediPharma (HMP). Primary endpoint: Number of Participants with any Adverse Event. Started Aug 2019; status: completed.
02
Drugs
sovleplenib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT03951623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03951623.